Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study

OBJECTIVE: To assess chemotherapeutic regimens for refractory acute myeloid leukemia (AML) and middle-and-high-risk myelodysplastic syndrome (MDS). METHODS: Between 2004 and 2014, 44 patients with refractory AML and 36 patients with MDS were treated with new priming regimens (CHAG, CHTG, CHMG, or CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaorong, Wang, Jin, Xu, Yan, Zhang, Wanggang, Liu, Jie, Cao, Xingmei, He, Aili, Wang, Fangxia, Gu, Liufang, Lei, Bo, Wang, Jianli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920259/
https://www.ncbi.nlm.nih.gov/pubmed/27382304
http://dx.doi.org/10.2147/OTT.S96427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920259/
https://www.ncbi.nlm.nih.gov/pubmed/27382304
http://dx.doi.org/10.2147/OTT.S96427

Ejemplares similares